1. Heart Transplantation for Early-Onset Anthracycline-Induced Cardiomyopathy Within 5 Months of Chemotherapy Completion
- Author
-
Kaskinen, Anu K., Helle, Emmi, Pihkala, Jaana, Jahnukainen, Timo, Kanerva, Jukka, Mäyränpää, Mikko I., Lemström, Karl, Mattila, Ilkka, Ojala, Tiina, Clinicum, HUS Children and Adolescents, Children's Hospital, Kivelä Lab, STEMM - Stem Cells and Metabolism Research Program, University of Helsinki, University Management, Department of Pathology, HUSLAB, Department of Surgery, III kirurgian klinikka, HUS Heart and Lung Center, Lastenkirurgian yksikkö, and Medicum
- Subjects
musculoskeletal diseases ,FS, fractional shortening ,acute heart failure ,LV, left ventricle/ventricular ,Imaging Vignette ,cardiac transplantation ,3126 Surgery, anesthesiology, intensive care, radiology ,HF, heart failure ,ACM, anthracycline-induced cardiomyopathy ,HTx, heart transplantation ,Clinical Vignette ,pediatric surgery ,EMB, endomyocardial biopsy ,cancer ,EF, ejection fraction ,cardiomyopathy - Abstract
A 9-year-old boy developed progressive anthracycline-induced cardiomyopathy three months after completion of chemotherapy for osteosarcoma. Five months after completion of chemotherapy, at the age of 10 years, heart transplantation was performed. At 29 months since transplantation, the patient remains free of rejection and recurrence of osteosarcoma. (Level of Difficulty: Intermediate.), Central Illustration
- Published
- 2021